These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 32975313)

  • 61. Association between advanced NSCLC T790 M EGFR-TKI secondary resistance and prognosis: A observational study.
    Wang Y; Wei Y; Ma X; Ma X; Gong P
    Medicine (Baltimore); 2018 Jul; 97(28):e11346. PubMed ID: 29995771
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC.
    Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K
    J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Intracranial control and survival outcome of tyrosine kinase inhibitor (TKI) alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer.
    Sung S; Lee SW; Kwak YK; Kang JH; Hong SH; Kim YS
    J Neurooncol; 2018 Aug; 139(1):205-213. PubMed ID: 29644484
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor.
    Zeng Z; Yan HH; Zhang XC; Zhong WZ; He YY; Guan JL; Niu FY; Xie Z; Huang YS; Xu CR; Dong S; Wu YL
    Lung Cancer; 2014 Nov; 86(2):219-24. PubMed ID: 25263853
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer.
    Koo HJ; Kim MY; Park S; Lee HN; Kim HJ; Lee JC; Kim SW; Lee DH; Choi CM
    Radiology; 2018 Oct; 289(1):227-237. PubMed ID: 30015588
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 68. [Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer].
    Zhao LD; Li JL; Wang Y; Wang B; Wang HY; Hao XZ; Cui CX; Zhang XR; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):217-21. PubMed ID: 21575523
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
    Kogure Y; Saka H; Oki M; Saito TI; Ahmed SN; Kitagawa C; Imaizumi K
    PLoS One; 2015; 10(8):e0135393. PubMed ID: 26262682
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
    Sun Y; Wu M; Zhou M; Luo X; Guo Y; Bai H; Zhang Z; Tian W; Wang X; Bai Y; Zhu X; Pan H; Deng Y; Hu H; Xia J; Hao X; Han L; Wei M; Liu Y; Zeng M
    BMC Cancer; 2020 Jul; 20(1):646. PubMed ID: 32660443
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Overall survival and prognostic factors in patients with spinal metastases from lung cancer treated with and without epidermal growth factor receptor tyrosine kinase inhibitors.
    Dohzono S; Sasaoka R; Takamatsu K; Nakamura H
    Int J Clin Oncol; 2017 Aug; 22(4):698-705. PubMed ID: 28361340
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
    Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC.
    Wang BX; Ou W; Mao XY; Liu Z; Wu HQ; Wang SY
    Clin Neurol Neurosurg; 2017 Sep; 160():96-100. PubMed ID: 28704781
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Skin problems and EGFR-tyrosine kinase inhibitor.
    Kozuki T
    Jpn J Clin Oncol; 2016 Apr; 46(4):291-8. PubMed ID: 26826719
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices.
    Singh-Kandah S; Wang K; Xia K; Lain Johnson A; D'Andrea DM; Shu CA; Bray Dougherty L; Gallitano SM
    Clin J Oncol Nurs; 2024 Sep; 28(5):1-8. PubMed ID: 39324708
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and the need for multiple medical and procedural therapies.
    Olamiju B; Bhullar S; Coleman EL; Leventhal JS
    J Am Acad Dermatol; 2021 Mar; 84(3):806-808. PubMed ID: 32526318
    [No Abstract]   [Full Text] [Related]  

  • 78. Usefulness of Noninvasive Management With the Gutter Method for Epidermal Growth Factor Receptor Inhibitor-Induced Paronychia, Pyogenic Granuloma-Like Lesion, and Ingrown Nail.
    Agematsu A; Kamata M; Namiki K; Yabuuchi Y; Nagata M; Tada Y
    JAMA Dermatol; 2022 May; 158(5):583-585. PubMed ID: 35416917
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effective and enduring surgical treatment for targeted therapy-related paronychia: A retrospective study.
    Liu TH; Wu SY; Tsai SL; Wu CW; Hou CC; Lai CY; Tzeng YS
    Medicine (Baltimore); 2022 Oct; 101(42):e31208. PubMed ID: 36281135
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Red light emitting diode as an adjuvant treatment for epidermal growth factor receptor inhibitors-induced paronychia.
    Jornsamer C; Theerawattanawit C; Wichayachakorn C; Panchaprateep R; Kerr SJ; Asawanonda P; Rerknimitr P
    J Dermatolog Treat; 2022 Jun; 33(4):1990-1994. PubMed ID: 33961534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.